Multivariate analyses showed that erlotinib was a marker of longer PFS ( HR = @ ; P = @ ) , whereas high BCL@L@ expression was a marker of longer PFS ( HR = @ ; P = @ ) and overall survival ( HR = @ ; P = @ ) .